patent.fyi
Applications  /  US 2026/0355146
United States Patent Application Publication

US 2026/0355146 A1

Published
Nov 12, 2026
Filed
Jun 23, 2026
Earliest date on the face
Dec 25, 2023
Classification
A61K 31/352
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Topical nerve growth factor

What ifWhat if topical recombinant human nerve growth factor supports epithelial repair in neurotrophic keratitis?
Claim language“7,8-dihydroxyflavone or a pharmaceutically acceptable salt thereof”

A sterile aqueous drop delivers the protein to the ocular surface. The protein activates its receptor on corneal sensory neurons and supports epithelial healing in eyes with impaired corneal innervation.

1.1Autologous serum eye drops

What ifWhat if autologous serum drops support repair of a persistent corneal epithelial defect?
Claim language“7,8-dihydroxyflavone or a pharmaceutically acceptable salt thereof”

Blood from the subject clots, and centrifugation separates the serum. Sterile saline dilutes the serum for topical delivery of proteins and growth factors that support epithelial cell migration and attachment.

1.1Hyaluronate tear film lubrication

What ifWhat if preservative-free sodium hyaluronate drops reduce ocular surface friction in dry eye disease?
Claim language“7,8-dihydroxyflavone or a pharmaceutically acceptable salt thereof”

A sterile aqueous solution delivers dissolved sodium hyaluronate from a single-dose container. The polymer retains water and increases tear film viscosity, reducing friction between the eyelid and the ocular surface during blinking.

1.1Amniotic membrane surface cover

What ifWhat if an amniotic membrane covers a persistent corneal epithelial defect during repair?
Claim language“7,8-dihydroxyflavone or a pharmaceutically acceptable salt thereof”

A retaining ring holds a cryopreserved amniotic membrane against the ocular surface. The membrane covers the defect, reduces direct contact with the blinking eyelid, and provides a substrate that supports epithelial migration.

1.1Silicone punctal tear retention

What ifWhat if a silicone punctal plug retains tears on the ocular surface in aqueous-deficient dry eye disease?
Claim language“7,8-dihydroxyflavone or a pharmaceutically acceptable salt thereof”

A plug sized to the lower lacrimal punctum occupies the opening, and a flange rests at the lid margin. The plug restricts drainage into the nasolacrimal system and increases tear residence time on the ocular surface.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Topical administration in veterinary ophthalmology

A veterinary clinic uses a sterile ophthalmic formulation containing 7,8-dihydroxyflavone to administer the compound to a dog with a persistent corneal epithelial defect. A clinician examines the cornea with fluorescein and records the dimensions of the stained area. The clinician instills the formulation into the lower conjunctival sac and measures the stained area again at follow-up visits.

Component substitution

Nerve growth factor as the active ingredient

An ophthalmic formulation for neurotrophic keratitis uses recombinant human nerve growth factor in place of 7,8-dihydroxyflavone. The protein is dissolved in a sterile, buffered aqueous vehicle and packaged in single-use containers under refrigerated storage. A dropper delivers the formulation into the lower conjunctival sac, where the fluid mixes with the tear film and spreads across the cornea.

Cyclodextrin carrier for aqueous eye drops

A sterile ophthalmic formulation uses hydroxypropyl beta-cyclodextrin in place of an organic cosolvent to carry 7,8-dihydroxyflavone in water. The cyclodextrin is dissolved in buffered water and mixed with the compound to form a soluble inclusion complex. The resulting solution is sterile-filtered and filled into single-use droppers for topical instillation.

Parameter or scale variation

Metered drops for a retention study

Two calibrated ophthalmic dispensers deliver the same concentration of 7,8-dihydroxyflavone in nominal drop volumes of 10 and 30 microliters. Each dispenser delivers one drop per trial onto a curved corneal model coated with artificial tear fluid. An absorbent collector below the model captures runoff, and gravimetric measurements compare the fraction of each drop retained after 30 seconds.

Combination with existing systems

Drug delivery with a scleral lens

A rigid gas-permeable scleral lens vaults the cornea and holds a fluid reservoir between its back surface and the ocular surface. Before insertion, the lens bowl is filled with a sterile, preservative-free ophthalmic formulation containing 7,8-dihydroxyflavone. The lens is seated on the sclera, and the reservoir holds the formulation against the cornea until the lens is removed.

Automated or data-driven variant

Image analysis of corneal defect closure

A slit-lamp camera captures fluorescein images before the first administration of 7,8-dihydroxyflavone and at follow-up examinations. Software uses a calibration image to convert pixel counts to square millimeters and segments the stained defect boundary within the corneal outline. The software stores each image, the measured defect area, and the time since administration so that a clinician can review the change over time.

Specific version of a part

Micronized ophthalmic suspension

A preservative-free, buffered aqueous vehicle carries micronized 7,8-dihydroxyflavone, with hypromellose increasing viscosity to slow settling. The contents are mixed before a single-dose dropper delivers the suspension into the lower conjunctival sac.

Petrolatum ophthalmic ointment

A sterile ophthalmic ointment disperses micronized 7,8-dihydroxyflavone in a white petrolatum and mineral oil base. A narrow ribbon applied inside the lower eyelid spreads across the ocular surface with blinking.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 9,895,344 B2
Published
Feb 20, 2018
Filed
Jul 23, 2009
Class
A61K 31/353
Document BUS 10,945,989 B2
Published
Mar 16, 2021
Filed
Sep 14, 2018
Class
A61K 31/352
Claim 1
Document A
Document B
1.1administering to a subject an effective amount of 7,8-dihydroxyflavone or a pharmaceutically acceptable salt thereof.
The methods include administering to a subject a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof.
A · US 9,895,344 B2 · ¶ 6
The present invention relates to methods of restoring brain development in individuals with Down syndrome with a flavone derivative, 7,8-dihydroxyflavone (7,8-DHF).
B · US 10,945,989 B2 · abstract

An empty cell means only that no passage was reproduced there.

Statements in these documents
Preclinical evidence indicates that BDNF might be useful as a therapeutic agent for various neurologic and neuropsychiatric disorders; however, the in vivo instability of such a peptide therapy limits its usefulness.
A · US 9,895,344 B2 · ¶ 4
A further method of promoting neuroprotection in a subject is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof.
A · US 9,895,344 B2 · ¶ 6
The molecular mechanisms underlying brain development alterations are likely to be manifold, due to the complexity of gene imbalance in DS, and no therapies currently exist for the rescue of neurocognitive impairment in DS.
B · US 10,945,989 B2 · ¶ 4
The present invention relates to methods of restoring brain development in individuals with Down syndrome.
B · US 10,945,989 B2 · ¶ 2
Cite aspatent.fyi, US 2026/0355146 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355146/, SHA-256 ba360e8016267c83f61c197eb93cb8a77172d707a0b10cf9b2d2d7c1136a68bb
First published
Permanent addresshttps://patent.fyi/US20260355146/
Content fingerprint (SHA-256)ba360e8016267c83f61c197eb93cb8a77172d707a0b10cf9b2d2d7c1136a68bb
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi